Literature DB >> 8127151

Epstein-Barr virus (EBV) can immortalize B-cll cells activated by cytokines.

V Wendel-Hansen1, J Sällström, P O De Campos-Lima, G Kjellström, A Sandlund, A Siegbahn, M Carlsson, K Nilsson, A Rosén.   

Abstract

B-type of chronic lymphocytic leukemia (B-CLL) cells are inert to the potent transforming action of Epstein-Barr virus (EBV). The mitogenic action of Staphylococcus aureus Cowan I (SAC), MP6-thioredoxin, and interleukin 2 (IL-2), agents previously shown to induce proliferation in normal as well as in B-CLL cells, lifted this block, and EBV-positive cell lines could be established. It was not possible to establish cell lines of leukemic origin from cultures that were incubated with EBV alone or cytokine mix alone. CLL-cells infected with EBV only, expressed the viral nuclear antigen complex (EBNA), but not the viral latent membrane protein (LMP). They were not activated as measured by cell size and 3H-thymidine incorporation. In contrast, cells incubated with EBV and cytokine mix expressed both EBNA and LMP in parallel with enlargement and increased 3H-thymidine incorporation. These results emphasize that LMP expression is a prerequisite for growth transformation and immortalization and that cytokine activation signals are required for its expression in B-CLLs. Cells incubated with SAC/MP6-thioredoxin/IL-2 did not express any of the viral antigens, but were activated with regard to the mentioned parameters. Nine cell lines were established from six patients. From each of the three patients, we obtained 'twin'-pair lines: one corresponding to the malignant cell and the other to a normal B-lymphoblastoid cell. Thus, malignant and normal B-cell counterparts, from the very same donor, are at hand for comparative studies. The cell lines have been carried out for more than 12 months in culture. We conclude that B-CLL that are refractory to EBV-transformation can be rendered susceptible through in vitro cytokine activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8127151

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  21 in total

1.  Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.

Authors:  Kwan-Ki Hwang; Xi Chen; Daniel M Kozink; Marietta Gustilo; Dawn J Marshall; John F Whitesides; Hua-Xin Liao; Rosa Catera; Charles C Chu; Xiao-Jie Yan; Micah A Luftig; Barton F Haynes; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-12-12       Impact factor: 22.113

2.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

3.  AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.

Authors:  Tasneem Motiwala; Nicola Zanesi; Jharna Datta; Satavisha Roy; Huban Kutay; Allyn M Checovich; Mohamed Kaou; Yiming Zhong; Amy J Johnson; David M Lucas; Nyla A Heerema; John Hagan; Xiaokui Mo; David Jarjoura; John C Byrd; Carlo M Croce; Samson T Jacob
Journal:  Blood       Date:  2011-10-14       Impact factor: 22.113

4.  Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

Authors:  Riccardo Dolcetti; Antonino Carbone
Journal:  Infect Agent Cancer       Date:  2010-11-22       Impact factor: 2.965

5.  A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.

Authors:  Sivasubramanian Baskar; Jessica M Suschak; Ivan Samija; Ramaprasad Srinivasan; Richard W Childs; Steven Z Pavletic; Michael R Bishop; Christoph Rader
Journal:  Blood       Date:  2009-08-10       Impact factor: 22.113

6.  Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS).

Authors:  M Kvarnstrom; E Sidorova; J Nilsson; C Ekerfelt; M Vrethem; O Soderberg; M Johansson; A Rosen; J Ernerudh
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

7.  Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.

Authors:  Crystina L Kriss; Javier A Pinilla-Ibarz; Adam W Mailloux; John J Powers; Chih-Hang Anthony Tang; Chang Won Kang; Nicola Zanesi; Pearlie K Epling-Burnette; Eduardo M Sotomayor; Carlo M Croce; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Blood       Date:  2012-06-12       Impact factor: 22.113

8.  Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.

Authors:  A Veronese; F Pepe; J Chiacchia; S Pagotto; P Lanuti; S Veschi; M Di Marco; A D'Argenio; I Innocenti; B Vannata; F Autore; M Marchisio; D Wernicke; F Verginelli; G Leone; L Z Rassenti; T J Kipps; R Mariani-Costantini; L Laurenti; C M Croce; R Visone
Journal:  Leukemia       Date:  2014-04-15       Impact factor: 11.528

9.  Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.

Authors:  Tasneem Motiwala; Sarmila Majumder; Huban Kutay; David Spencer Smith; Donna S Neuberg; David M Lucas; John C Byrd; Michael Grever; Samson T Jacob
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

10.  A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells.

Authors:  Eva Mikaelsson; Anders Österborg; Mahmood Jeddi-Tehrani; Parviz Kokhaei; Mahyar Ostadkarampour; Reza Hadavi; Mehran Gholamin; Mehdi Akhondi; Fazel Shokri; Hodjattallah Rabbani; Håkan Mellstedt
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.